Diabetes & Metabolic Medicines · LP-059
Gliclazide Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-059Diabetes & Metabolic Medicines
- Generic identity
- GliclazideTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-059
- Generic identity
- Gliclazide
- Presentation
- Tablet
- Catalogue strength
- 80 mg immediate-release; 30 mg modified-release; 60 mg modified-release
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Gliclazide.
- Dosage form: tablet.
- Catalogue strength / concentration: 80 mg immediate-release; 30 mg modified-release; 60 mg modified-release.
- Catalogue pack: Blister 10 x 10 tablets.
- Catalogue category: Diabetes & Metabolic Medicines.
Layer 02 · Unresolved product-specific fields
- Exact finished-product composition, excipients and manufacturing specification.
- Release technology/dissolution specification for each IR/MR variant, controlled SKU mapping and any variant-specific score/divisibility.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
Identity note
External product information illustrates that immediate-release and modified-release gliclazide are deliberately distinguished and that switching requires controlled instructions. Those instructions are not adopted for LP-059.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 80 mg immediate-release | Tablet | Immediate release | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | Preserve the immediate-release or modified-release descriptor. Do not convert strengths or import comparator switching instructions into Luang Pharma labelling. |
| B | 30 mg modified-release | Tablet | Modified release | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | Preserve the immediate-release or modified-release descriptor. Do not convert strengths or import comparator switching instructions into Luang Pharma labelling. |
| C | 60 mg modified-release | Tablet | Modified release | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | Preserve the immediate-release or modified-release descriptor. Do not convert strengths or import comparator switching instructions into Luang Pharma labelling. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Gliclazide is a sulfonylurea used in selected type 2 diabetes management plans. It stimulates insulin release and can cause low blood glucose, particularly when intake or other clinical circumstances change. Immediate-release and modified-release presentations must be distinguished. This page offers general ingredient education, not Luang Pharma approved labeling, and does not provide a conversion between the catalogue’s different strengths or release forms.
Clinical context and therapeutic role
A clinician weighs expected glucose-lowering benefit against hypoglycaemia risk, considering age, frailty, meal regularity and renal or hepatic disease. Treatment is part of a wider diabetes plan that may include other medicines and risk-factor management. A change between immediate-release and modified-release gliclazide requires a specific prescribing decision. The patient should have an agreed monitoring and illness plan, with advice about reduced intake, fasting and suspected hypoglycaemia.
Selected safety context
Low blood glucose is the principal concern and can become severe. Symptoms such as sweating, shaking, unusual hunger or confusion should be recognized within the patient’s care plan; seizures or unconsciousness are emergencies. Missed meals, alcohol and interacting medicines can increase risk. Weight gain or gastrointestinal upset may occur. Pregnancy and significant renal or hepatic disease require review. Do not crush a modified-release product or substitute a different release form without confirmed instructions.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A diabetes-care professional should confirm the formulation, glycaemic objective, renal function and hypoglycaemia risk. The person should have an individualized monitoring and illness plan; this educational page does not supply dose-selection or conversion instructions.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07c checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: GliclazideArchived source classification: Public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| emc: Gliclazide 60 mg modified-release SmPC exampleArchived source classification: UK professional product information example | Source revision recorded: SmPC page last updated 31 January 2023; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-059.
Professional enquiries
Request product-specific evidence for LP-059.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.